Search results
Results from the WOW.Com Content Network
Scurvy is a deficiency disease (state of malnutrition) resulting from a lack of vitamin C (ascorbic acid). [1] Early symptoms of deficiency include weakness, fatigue, and sore arms and legs. [1] [2] Without treatment, decreased red blood cells, gum disease, changes to hair, and bleeding from the skin may occur.
The design for a medical study in 1743 that was never carried out may have inspired James Lind’s groundbreaking clinical trial that determined the treatment for scurvy. A 1747 study found the ...
Dosage typically includes information on the number of doses, intervals between administrations, and the overall treatment period. [3] For example, a dosage might be described as "200 mg twice daily for two weeks," where 200 mg represents the individual dose, twice daily indicates the frequency, and two weeks specifies the duration of treatment.
James Lind FRSE FRCPE (4 October 1716 – 13 July 1794) was a Scottish physician. He was a pioneer of naval hygiene in the Royal Navy.By conducting one of the first ever clinical trials, [1] [2] [3] he developed the theory that citrus fruits cured scurvy.
According to the Centers for Disease Control and Prevention (CDC), roughly 37 percent of adults in the U.S. reported getting less than the recommended seven or more hours of sleep in 2022.
Pre-exposure prophylaxis (PrEP), is the use of medications to prevent the spread of disease in people who have not yet been exposed to a disease-causing agent. Vaccination is the most commonly used form of pre-exposure prophylaxis; other forms of pre-exposure prophylaxis generally involve drug treatment, known as chemoprophylaxis.
A 2012 meta-analysis of fluoxetine and venlafaxine concluded that statistically and clinically significant treatment effects were observed for each drug relative to placebo irrespective of baseline depression severity; some of the authors however disclosed substantial relationships with pharmaceutical industries.
The Comprehensive Drug Abuse Prevention and Control Act of 1970, Pub. L. 91–513, 84 Stat. 1236, enacted October 27, 1970, is a United States federal law that, with subsequent modifications, requires the pharmaceutical industry to maintain physical security and strict record keeping for certain types of drugs. [1]